Literature DB >> 20418675

Cystic renal tumors: new entities and novel concepts.

Holger Moch1.   

Abstract

Cystic renal neoplasms and renal epithelial stromal tumors are diagnostically challenging and represent some novel tumor entities. In this article, clinical and pathologic features of established and novel entities are discussed. Predominantly cystic renal tumors include cystic nephroma/mixed epithelial and stromal tumor, synovial sarcoma, and multilocular cystic renal cell carcinoma. These entities are own tumor entities of the 2004 WHO classification of renal tumors. Tubulocystic carcinoma and acquired cystic disease-associated renal cell carcinoma are neoplasms with an intrinsically cystic growth pattern. Both tumor types should be included in a future WHO classification as novel entities owing to their characteristic features. Cysts and clear cell renal cell carcinoma frequently coexist within the kidneys of patients with von Hippel-Lindau disease. Sporadic clear cell renal cell carcinomas often contain cysts, usually as a minor component. Some clear cell renal cell carcinomas have prominent cysts, and multilocular cystic renal cell carcinoma is composed almost exclusively of cysts. Recent molecular findings suggest that clear cell renal cancer may develop through cyst-dependent and cyst-independent molecular pathways.

Entities:  

Mesh:

Year:  2010        PMID: 20418675     DOI: 10.1097/PAP.0b013e3181d98c9d

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  17 in total

1.  Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential.

Authors:  Maria Rosaria Raspollini; Francesca Castiglione; Guido Martignoni; Liang Cheng; Rodolfo Montironi; Antonio Lopez-Beltran
Journal:  Virchows Arch       Date:  2015-10-05       Impact factor: 4.064

Review 2.  An overview of non-invasive imaging modalities for diagnosis of solid and cystic renal lesions.

Authors:  Ravinder Kaur; Mamta Juneja; A K Mandal
Journal:  Med Biol Eng Comput       Date:  2019-11-21       Impact factor: 2.602

3.  Primary renal carcinoid tumor: A rare cystic renal neoplasm.

Authors:  Jung-Hee Yoon
Journal:  World J Radiol       Date:  2013-08-28

4.  [Cystic renal neoplasms. New entities and molecular findings].

Authors:  H Moch
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  Tubulocystic renal carcinoma: a clinical perspective.

Authors:  Milan Hora; Tomáš Urge; Viktor Eret; Petr Stránský; Jiří Klečka; Boris Kreuzberg; Jiří Ferda; Luboš Hyršl; Ján Breza; Petra Holečková; Michal Mego; Michal Michal; Fredrik Petersson; Ondřej Hes
Journal:  World J Urol       Date:  2010-11-24       Impact factor: 4.226

Review 6.  Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.

Authors:  Ming Zhao; Xiaodong Teng; Guoqing Ru; Zhongsheng Zhao; Qinqin Hu; Likai Han; Xianglei He
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 7.  [Hereditary renal tumors: More common than expected?].

Authors:  A Agaimy; A Hartmann
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

8.  [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

9.  Multilocular cystic renal cell carcinoma: a rare entity.

Authors:  Atin Singhai; Suresh Babu; Nidhi Verma; Vishwajeet Singh
Journal:  BMJ Case Rep       Date:  2013-04-03

10.  Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum.

Authors:  Maria Tretiakova; Vikas Mehta; Masha Kocherginsky; Agata Minor; Steven S Shen; Sahussapont Joseph Sirintrapun; Jorge L Yao; Isabel Alvarado-Cabrero; Tatjana Antic; Scott E Eggener; Maria M Picken; Gladell P Paner
Journal:  Virchows Arch       Date:  2018-05-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.